BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
BC Week In Review | Jun 11, 2012
Company News

Drais, Seldar, Astellas deal

Astellas and Drais partnered to form virtual company - Seldar Pharma Inc. - that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which will be managed by Drais' executive team, raised $13...
BC Extra | Jun 5, 2012
Company News

Astellas, Drais form newco to develop Astellas' IBS product

Astellas Pharma Inc. (Tokyo:4503) and Drais Pharmaceuticals Inc. (Bridgewater, N.J.) partnered to form virtual company -- Seldar Pharma Inc. -- that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which...
BC Innovations | Aug 27, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Neurology Pain Gastrin-releasing peptide receptor (GRPR; GRP-R) A study in mice suggests that targeting GRP-R could help relieve itching. In mice, intrathecal delivery of bombesin-saporin, a...
BC Week In Review | Nov 17, 2008
Company News

Bracco Imaging S.p.A., Marillion deal

Bracco granted Marillion exclusive, worldwide rights to develop and commercialize 177Lu-AMBA to treat hormone-resistant prostate cancer (HRPC) and advanced breast cancer. The radiotherapeutic combined with an agonist of gastrin-releasing peptide receptor (GRP-R) is in Phase...
Items per page:
1 - 7 of 7